BioLinker
Cotia, Brazil
◆ About BioLinker
Brazilian biotech startup that develops and manufactures recombinant proteins using synthetic biology and genetic engineering for research, diagnostics, and industrial applications.
◆ What sets it apart
Its proprietary Sol platform and cell-free protein-synthesis technology enable faster, customizable, and scalable recombinant-protein discovery and production.
◆ Sectors
◆ Business
Modeltransactional
CustomerResearch laboratories, biotechnology and pharmaceutical companies, diagnostic developers, industrial manufacturers, agricultural companies, and innovation centers
◆ Notable
- Developed the proprietary Sol platform for protein discovery, optimization, and production
- Became one of the few companies worldwide commercializing its own cell-free protein-expression kit
- Developed lyophilized SARS-CoV-2 proteins for vaccine, drug, and diagnostic research
- Supported by FAPESP PIPE and incubated at the University of São Paulo's CIETEC
◆ Funding rounds
◆ Explore the market
◆ FAQ
What does BioLinker do?
Brazilian biotech startup that develops and manufactures recombinant proteins using synthetic biology and genetic engineering for research, diagnostics, and industrial applications.
Where is BioLinker based?
BioLinker is based in Cotia, Brazil, founded in 2018.
How much has BioLinker raised?
BioLinker has raised $1.7M in tracked funding and is currently at the seed stage.
Who has invested in BioLinker?
Investors in BioLinker include Marcos Pontes.